Finally, following phase I study (ORR, 53%; CR, 41% in the first 17 enrolled patients) [82], an ongoing study is comparing lenalidomide combined with brentuximab vedotin or with rituximab in R/R DLBCL patients stratified by CD30 expression (≥ 1% vs. < 1%, NCT04404283) [83]. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.